Study: Rivaroxaban is effective, but increases bleeding risk

02/8/2013 | Forbes · MedPage Today (free registration)

The anticoagulant rivaroxaban was effective at preventing venous thromboembolism in patients with acute illnesses, but it was associated with a significant increase in bleeding risk, according to a study published in the New England Journal of Medicine. The study compared rivaroxaban with enoxaparin.

View Full Article in:

Forbes · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC